Xeris Biopharma Holdings, Inc. (XERS)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$10.13+11.56%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.8B
- Forward P/E
- 26.0
- 52-week range
- $5.25 – $11.33
- 52-week change
- +9.66%
- EPS (trailing)
- −$0.10
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $292M (+43.72%)
- Net income
- $554K
- Operating margin
- 8.5%
- Diluted EPS
- $0.00
From the company’s annual report on SEC EDGAR.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Headquarters: Chicago, United States · 435 employees · xerispharma.com